J&J’s Tecvayli/Darzalex nod is the second under a new priority voucher scheme.
ApexOnco Front Page
Recent articles
Rinzimetostat efficacy wanes further as the company moves into phase 3.
The company will imminently start its third pivotal trial of PF-08634404.
The Rainfol-04 trial in platinum-sensitive ovarian cancer will start next year.
But the Day One deal is still 29% below where the shares stood at the start of this year.
The company ditches lorigerlimab in prostate cancer.
New detalimogene bladder cancer data send the minnow’s stock up 47%.
The response rate jumps to 30% with higher doses of IMA402.
